{"protocolSection": {"identificationModule": {"nctId": "NCT00545844", "orgStudyIdInfo": {"id": "0476-383"}, "secondaryIdInfos": [{"id": "MK0476-383"}, {"id": "2007_024"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Singulair(R) In Asthma And Allergic Rhinitis (0476-383)", "officialTitle": "An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-01-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-01-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-16", "studyFirstSubmitQcDate": "2007-10-16", "studyFirstPostDateStruct": {"date": "2007-10-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2008-12-19", "resultsFirstSubmitQcDate": "2009-07-07", "resultsFirstPostDateStruct": {"date": "2009-08-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 313, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "montelukast sodium", "interventionNames": ["Drug: montelukast sodium"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment", "armGroupLabels": ["1"], "otherNames": ["Singulair"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control", "description": "Asthma control was assessed by the Canadian Asthma Consensus Guidelines at week 0 and week 8. Patients were considered uncontrolled if they answered \"yes\" to at least 2 of the 8 asthma control parameters.", "timeFrame": "8 weeks (from Week 0 to Week 8)"}], "secondaryOutcomes": [{"measure": "The Mean Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Score", "description": "Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) consists of 14 questions to assess patient's overall quality of life related to allergic rhinitis on a scale of 0 (least impairment) to 6 (greatest impairment). The score is the mean of the 14 questions, ranging from 0 to 6. Change is computed as Week 8 score - Week 0 score", "timeFrame": "8 weeks (from Week 0 to Week 8)"}, {"measure": "Effectiveness of Montelukast Therapy Used in Combination With Inhaled Corticosteroids or Inhaled Corticosteroids / Long-Acting Beta 2-Agonist in Improving the Symptoms of Asthma Using the Asthma Control Questionnaire (ACQ)", "description": "The Asthma Control Questionnaire consists of 7 specific questions that were used to assess patient asthma control at week 0 and week 8. The mean score per question is used to determine the level of control, with a final score ranging from 0 (well-controlled) to 6 (extremely poorly controlled) units on a scale.", "timeFrame": "8 weeks (from Week 0 to Week 8)"}], "otherOutcomes": [{"measure": "Patient Global Satisfaction", "description": "At week 0 and week 8, patients were asked to complete a single question describing how satisfied they were regarding their asthma controller medication.", "timeFrame": "8 weeks (from Week 0 to Week 8)"}, {"measure": "Physician Global Satisfaction", "description": "At week 0 and week 8, physicians were asked to complete a single question describing how satisfied they were regarding their patient's asthma controller medication.", "timeFrame": "8 weeks (from Week 0 to Week 8)"}, {"measure": "Patient Global Allergic Rhinitis Symptoms Assessment", "description": "At week 0 and week 8, patients were asked to complete one question describing their perception of their allergic rhinitis symptoms.", "timeFrame": "8 weeks (from Week 0 to Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage\n* Peak expiratory flow is \\> or = 80% of predicted value on the day of visit 1\n* Uncontrolled as per Canadian asthma consensus guidelines\n\nExclusion Criteria:\n\n* Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms\n* Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "19557208", "type": "DERIVED", "citation": "Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS, Schellenberg RR, McIvor RA. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J. 2009 May-Jun;16 Suppl A(Suppl A):17A-31A. doi: 10.1155/2009/145071."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The anticipated Enrollment was 440, with an expected rate of 20% over the 8-week period, thus 369 patients should complete the study.", "recruitmentDetails": "First 25 asthmatic patients seen consecutively at each site were invited to participate.\n\nTreatment phase: From the Survey population, blocks of 8 were allowed to participate. All subjects took 1 tablet of montelukast 10 mg once a day at bedtime.\n\nFirst patient in: APR-02-2007 Last patient out: JAN-25-2008", "groups": [{"id": "FG000", "title": "All Patients", "description": "montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment\n\nPatients with comorbid allergic rhinitis and uncontrolled asthma were invited to participate in the treatment phase of the study. Of the 1004 patients who completed the survey phase, there were 319 eligible patients who advanced and participated in the treatment phase. Of the 319 eligible patients who advanced to the treatment phase 6 did not meet inclusion criteria leaving 313 patients."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "313"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "301"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Patients", "description": "montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment\n\nPatients with comorbid allergic rhinitis and uncontrolled asthma were invited to participate in the treatment phase of the study. Of the 1004 patients who completed the survey phase, there were 319 eligible patients who advanced and participated in the treatment phase. Of the 319 eligible patients who advanced to the treatment phase 6 did not meet inclusion criteria leaving 313 patients."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "313"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.1", "spread": "17.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "199"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "114"}]}]}]}, {"title": "Inhaled Corticosteroids or Inhaled Corticosteroids / Long-Acting Beta 2-Agonist Use", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Inhaled Corticosteroids Only", "categories": [{"measurements": [{"groupId": "BG000", "value": "154"}]}]}, {"title": "Inhaled Corticosteroids/Long-Acting Beta 2-Agonist", "categories": [{"measurements": [{"groupId": "BG000", "value": "153"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "Allergic Rhinitis Diagnosis Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "131.4", "spread": "135.4"}]}]}]}, {"title": "Asthma Diagnosis Duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "147.6", "spread": "139.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control", "description": "Asthma control was assessed by the Canadian Asthma Consensus Guidelines at week 0 and week 8. Patients were considered uncontrolled if they answered \"yes\" to at least 2 of the 8 asthma control parameters.", "populationDescription": "319 patients advanced to the treatment phase and 313 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 301 patients who completed week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 0"}, {"id": "OG001", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "301"}]}], "classes": [{"title": "Uncontrolled", "categories": [{"measurements": [{"groupId": "OG000", "value": "312"}, {"groupId": "OG001", "value": "72"}]}]}, {"title": "Controlled", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "229"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "The Mean Change in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Overall Score", "description": "Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) consists of 14 questions to assess patient's overall quality of life related to allergic rhinitis on a scale of 0 (least impairment) to 6 (greatest impairment). The score is the mean of the 14 questions, ranging from 0 to 6. Change is computed as Week 8 score - Week 0 score", "populationDescription": "Based on ITT population; there were 286 patients with available data regarding the mean change in MiniRQLQ at week 8.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a Scale", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.45", "spread": "1.35"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Effectiveness of Montelukast Therapy Used in Combination With Inhaled Corticosteroids or Inhaled Corticosteroids / Long-Acting Beta 2-Agonist in Improving the Symptoms of Asthma Using the Asthma Control Questionnaire (ACQ)", "description": "The Asthma Control Questionnaire consists of 7 specific questions that were used to assess patient asthma control at week 0 and week 8. The mean score per question is used to determine the level of control, with a final score ranging from 0 (well-controlled) to 6 (extremely poorly controlled) units on a scale.", "populationDescription": "There were 313 patients who qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit; of these, 300 patients completed the ACQ at week 8.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a Scale", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 0"}, {"id": "OG001", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "300"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.03", "spread": "0.80"}, {"groupId": "OG001", "value": "0.92", "spread": "0.80"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patient Global Satisfaction", "description": "At week 0 and week 8, patients were asked to complete a single question describing how satisfied they were regarding their asthma controller medication.", "populationDescription": "319 patients advanced to the treatment phase and 313 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 301 patients who completed week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 0"}, {"id": "OG001", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "301"}]}], "classes": [{"title": "Very satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "136"}]}]}, {"title": "Satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "110"}]}]}, {"title": "Neither satisfied or dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Very dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "McNemar-Bowker test is McNemar chi-squared statistic for binary matched pairs, with Bowker chi-squared fit test of symmetry model (tests all rows of data) (cf. Agresti, 2007)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Physician Global Satisfaction", "description": "At week 0 and week 8, physicians were asked to complete a single question describing how satisfied they were regarding their patient's asthma controller medication.", "populationDescription": "319 patients advanced to the treatment phase and 313 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 301 patients who completed week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 0"}, {"id": "OG001", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "301"}]}], "classes": [{"title": "Very satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "135"}]}]}, {"title": "Satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "110"}]}]}, {"title": "Neither satisfied or dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "25"}]}]}, {"title": "Very dissatisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "McNemar-Bowker test is McNemar chi-squared statistic for binary matched pairs, with Bowker chi-squared fit test of symmetry model (tests all rows of data) (cf. Agresti, 2007)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Patient Global Allergic Rhinitis Symptoms Assessment", "description": "At week 0 and week 8, patients were asked to complete one question describing their perception of their allergic rhinitis symptoms.", "populationDescription": "319 patients advanced to the treatment phase and 313 patients qualified for inclusion in the intent to treat (ITT) analysis and completed the first visit. The following results are based on the 301 patients who completed week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks (from Week 0 to Week 8)", "groups": [{"id": "OG000", "title": "Treatment Phase (All Patients) Week 0"}, {"id": "OG001", "title": "Treatment Phase (All Patients) Week 8"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "301"}]}], "classes": [{"title": "A non-issue as I do not have these symptoms", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "41"}]}]}, {"title": "Not really bothersome", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "129"}]}]}, {"title": "Bothersome a little of the time", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "77"}]}]}, {"title": "Bothersome some of the time", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "40"}]}]}, {"title": "Bothersome a good bit of the time", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "McNemar-Bowker test is McNemar chi-squared statistic for binary matched pairs, with Bowker chi-squared fit test of symmetry model (tests all rows of data) (cf. Agresti, 2007)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "McNemar-Bowker"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.3", "eventGroups": [{"id": "EG000", "title": "All Patients", "seriousNumAffected": 0, "seriousNumAtRisk": 313, "otherNumAffected": 11, "otherNumAtRisk": 313}], "otherEvents": [{"term": "Allergic reaction Not Otherwise Specified", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Asthma aggravated", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Swollen tongue", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Upset stomach", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Muscular pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 313}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada"]}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}